Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials
- PMID: 38261005
- DOI: 10.1007/s00228-024-03624-6
Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials
Abstract
Purpose: Propofol has become the sedative of choice for endoscopy and colonoscopy. However, it has shown associations with various adverse effects, specifically in the geriatric population. In contrast, remimazolam is a novel benzodiazepine, demonstrating a superior clinical safety profile. Hence, this systematic review and meta-analysis aims to clarify the efficacy and safety of remimazolam versus propofol in elderly patients (≥ 60 years) undergoing gastrointestinal endoscopic and colonoscopy procedures.
Methods: Electronic databases including PubMed, Cochrane Library, ScienceDirect, and Google Scholar were explored from inception till January 7, 2024. The Cochrane Risk of Bias Tool for Randomized Controlled Trials (RoB-2) was utilized to evaluate the quality of each included study reported in this meta-analysis.
Results: Seven randomized control trials were included, resulting in the pooling of 1,466 patients (remimazolam: 731 patients; propofol: 735 patients). Propofol demonstrated a significantly lower time to loss of consciousness (P < 0.00001, 4 studies, 784 patients) and a greater sedation success after first dose (P = 0.05, 5 studies, 1,271 patients). Remimazolam reported a significantly lower risk of bradycardia (P = 0.02, 5 studies, 1,323 patients), hypoxemia (P < 0.00001, 6 studies, 1,389 patients), and pain on injection site (P < 0.00001, 5 studies, 1,184 patients). No statistically significant differences in sedation time, number of supplemental doses, procedural parameters, and other adverse outcomes were reported.
Conclusion: As per the results of our analyses, propofol demonstrated comparatively superior efficacy, however, remimazolam demonstrated comparatively superior safety. The debatable evidence generated from this meta-analysis may not currently be powerful enough to advocate for the use of remimazolam in elderly patients undergoing gastrointestinal procedures; hence, further comprehensive studies are necessary in order to arrive at a robust conclusion.
Keywords: Colonoscopy; Elderly; Endoscopy; Meta-analysis; Propofol; Remimazolam.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Spiceland CM, Lodhia N (2018) Endoscopy in inflammatory bowel disease: role in diagnosis, management, and treatment. World J Gastroenterol 24(35):4014–4020. https://doi.org/10.3748/wjg.v24.i35.4014 - DOI - PubMed - PMC
-
- Al-Awabdy B, Wilcox CM (2013) Use of anesthesia on the rise in gastrointestinal endoscopy. World J Gastrointest Endosc 5(1):1–5. https://doi.org/10.4253/wjge.v5.i1.1 - DOI - PubMed - PMC
-
- Marik PE (2004) Propofol: therapeutic indications and side-effects. Curr Pharm Des 10(29):3639–3649. https://doi.org/10.2174/1381612043382846 - DOI - PubMed
-
- Fulton B, Sorkin EM, Propofol (1995) An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 50(4):636–657. https://doi.org/10.2165/00003495-199550040-00006 - DOI - PubMed
-
- Folino TB, Muco E, Safadi AO et al Propofol. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430884/
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
